Form 4: Fulgent Genetics' Chief Scientific Officer Gao Hanlin Reports Stock Transaction
SEC Form 4 Filing
Gao Hanlin, Chief Scientific Officer of Fulgent Genetics, reports a transaction involving the withholding of shares to cover tax obligations.
Summary
- On January 30, 2025, Fulgent Genetics' Chief Scientific Officer, Gao Hanlin, had 90 shares of common stock withheld to cover tax obligations.
- The shares were withheld to satisfy tax obligations arising from the vesting of restricted stock units granted on April 30, 2021.
- Following the transaction, Gao Hanlin directly owns 918,050 shares of Fulgent Genetics common stock.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing, indicating a neutral sentiment. It reflects standard executive compensation practices.
Industry Context
This is a routine filing related to executive compensation and stock ownership, common in publicly traded companies.
Stakeholder Impact
- The transaction has a minimal direct impact on shareholders, as it involves a small number of shares withheld for tax purposes.
Key Dates
| Date | Description |
|---|---|
| 04/30/2021 | Date of original grant of restricted stock units to Gao Hanlin. |
| 05/03/2021 | Date of Form 4 filing reporting the grant of restricted stock units. |
| 01/30/2025 | Date of the stock transaction (share withholding) to cover tax obligations. |
| 02/03/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.